Aktis Oncology Accelerates Targeted Radiopharmaceuticals for Solid Tumor Cancers
Aktis Oncology’s 225Ac radiopharmaceuticals target Nectin‑4 and B7‑H3 solid tumors, offering a precision radiation therapy that could reshape oncology treatment.
3 minutes to read